April 17 (Reuters) - Most doses of Eli Lilly's (LLY.N), opens new tab diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the U.S. Food and Drug Administration's website showed on Wednesday.
Drug companies are pricing diabetes medicines at almost 400 times the level necessary to make a profit, according to a new study.
Following in EU regulators' footsteps, the U.K. has reportedly launched a probe into potential suicide risks for popular diabetes and weight-loss drugs.
It’s been nearly a year since Novo Nordisk revealed a supply shortfall for its obesity blockbuster-to-be Wegovy. Now, it appears history is repeating for the company’s chief rival, Eli Lilly.
It’s been nearly a year since Novo Nordisk revealed a supply shortfall for its obesity blockbuster-to-be Wegovy. Now, it appears history is repeating for the company’s chief rival, Eli Lilly.
Eli's Biologic Trulicity (Dulaglutide) Receives Approval in the U.S.
Eli Lilly Generic Dulaglutide Receives Approval in the U.S.
Enforcement Report - Week of May 25, 2022
Eli Lilly’s tirzepatide — the type II diabetes candidate and Trulicity’s heir apparent, projected to be a megablockbuster drug within the next five years — has been waiting on the FDA to give it the OK. Yet according to cost watchdog ICER, there is still some doubt about just how useful it can be to patients when compared to top rivals.
Sanofi and Regeneron’s immunology blockbuster Dupixent was knocked down into second place as Eli Lilly’s diabetes medicine Trulicity took the top spot for January’s biggest TV ad spenders, according to the real-time TV ad trackers at iSpot.tv.